Medicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.36 and last traded at C$0.36, with a volume of 128723 shares changing hands. The stock had previously closed at C$0.37.

Medicenna Therapeutics Stock Performance

The company has a quick ratio of 4.65, a current ratio of 1.52 and a debt-to-equity ratio of 4.79. The company has a market cap of C$33.23 million, a PE ratio of -1.64 and a beta of 2.96. The stock’s 50 day simple moving average is C$0.46 and its two-hundred day simple moving average is C$0.68.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. As a group, research analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.